Loading…
Reliance Pharma Fund
Disclosed for 84 months, Sep 2012 to Aug 2019. This scheme is no longer reporting.Published as: RELIANCE PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹1,445 Cr
down ₹42.3 Cr vs Feb 2017
- Stocks held
Reliance Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In March 2017 it disclosed 17 stocks worth ₹1,445 Cr, down ₹42.3 Cr from Feb 2017. Its largest positions were Zydus Lifesciences Limited (9.8%), Aurobindo Pharma Limited (9.6%), Abbott India Limited (8.7%); the ten largest together made up 78.9% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 83.3% of its equity. Cash and debt stood at 0.4%. Compared with Feb 2017 the fund entered 1 new stock and exited 0.
Against 227 other Sectoral / Thematic funds
Concentration
98%
Top-10 weight is higher than 98% of peers
Breadth
4%
Holds more stocks than 4% of peers
Cash
6%
Holds more cash than 6% of peers
Holdings in March 2017
Download CSVEvery line the fund disclosed, with the change against Feb 2017. Click a column to sort; click a company to see every fund that owns it.
| Zydus Lifesciences Limited | 9.79% | up 0.02 pts | ₹141 Cr | down ₹3.8 Cr | Trimmed |
| Aurobindo Pharma Limited | 9.58% | up 0.24 pts | ₹138 Cr | down ₹41 L | Held |
| Abbott India Limited | 8.69% | down 0.33 pts | ₹126 Cr | down ₹8.5 Cr | Trimmed |
| Sanofi India Limited | 8.24% | up 0.64 pts | ₹119 Cr | up ₹6 Cr | Added |
| Sun Pharmaceutical Industries Limited | 8.10% | down 0.58 pts | ₹117 Cr | down ₹12 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 7.30% | up 0.48 pts | ₹106 Cr | up ₹4.1 Cr | Added |
| Lupin Limited | 7.00% | up 0.06 pts | ₹101 Cr | down ₹2 Cr | Trimmed |
| Cipla Limited | 6.98% | up 0.30 pts | ₹101 Cr | up ₹1.6 Cr | Added |
| Divi's Laboratories Limited | 6.72% | down 1.22 pts | ₹97.1 Cr | down ₹21 Cr | Trimmed |
| Thyrocare Technologies Limited | 6.45% | up 0.34 pts | ₹93.2 Cr | up ₹2.4 Cr | Added |
| Glenmark Pharmaceuticals Limited | 4.72% | down 0.26 pts | ₹68.2 Cr | down ₹5.9 Cr | Trimmed |
| Max India Limited | 4.28% | up 0.19 pts | ₹61.9 Cr | up ₹1 Cr | Added |
| Healthcare Global Enterprises Limited | 3.97% | down <0.01 pts | ₹57.4 Cr | down ₹1.7 Cr | Trimmed |
| IPCA Laboratories Limited | 3.47% | up 0.29 pts | ₹50.2 Cr | up ₹2.9 Cr | Added |
| Torrent Pharmaceuticals Limited | 2.31% | up 0.34 pts | ₹33.4 Cr | up ₹4.1 Cr | Added |
| Apollo Hospitals Enterprise Limited | 1.41% | up 1.41 pts | ₹20.4 Cr | up ₹20.4 Cr | New |
| Narayana Hrudayalaya Limited | 0.56% | down <0.01 pts | ₹8.1 Cr | down ₹29 L | Trimmed |
| Cash, TREPS & receivables | 0.42% | down 1.93 pts | ₹6 Cr | down ₹28.9 Cr | Trimmed |
What changed, Feb 2017 to Mar 2017
New New positions (1)
- Apollo Hospitals Enterprise Limited1.4% · ₹20.4 Cr
Exited Exited (0)
None.
Added Biggest additions
- Sanofi India Limitedup ₹6 Cr (+0.64% pts)
- Dr. Reddy's Laboratories Limitedup ₹4.1 Cr (+0.48% pts)
- Torrent Pharmaceuticals Limitedup ₹4.1 Cr (+0.34% pts)
- IPCA Laboratories Limitedup ₹2.9 Cr (+0.29% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Feb 2017, the weight rose most in Healthcare Services (+1.7 pts), and fell most in Pharmaceuticals & Biotechnology (−1.7 pts).
- Healthcare Services15.1% → 16.7%+1.7 pts
- Pharmaceuticals & Biotechnology84.9% → 83.3%−1.7 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Mar 2014 | Mar 2016 | Sep 2016 | Dec 2016 | Feb 2017 | Mar 2017 |
|---|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 92.8% | 97.4% | 83.9% | 83.8% | 84.9% | 83.3% |
| Healthcare Services | — | 0.8% | 14.3% | 16.2% | 15.1% | 16.7% |
Allocation in Mar 2017change vs Feb 2017
- Pharmaceuticals & Biotechnology (12)83.3%▼ 1.7 pts
- Healthcare Services (5)16.7%▲ 1.7 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal.
Cash & debt, Mar 2017
0.4%
▼ 1.9 pts vs Feb 2017
- Cash alone
- 0.4%
- cash and net receivables
- A year earlier
- 1.4%
- Mar 2016 · now ▼ 0.9 pts
- Last 12 months
- 0.4% – 3.6%
- lowest to highest · record 9.6% in Nov 2015
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.